| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.3390/V4113044 |
| P8608 | Fatcat ID | release_dq6ocowu5vbyzdq5hc4uhtl7me |
| P932 | PMC publication ID | 3509683 |
| P698 | PubMed publication ID | 23202515 |
| P5875 | ResearchGate publication ID | 233828829 |
| P50 | author | Raphael Duval | Q58324384 |
| P2093 | author name string | Mihayl Varbanov | |
| Chloé Geller | |||
| P2860 | cites work | Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats | Q24536078 |
| Survival of severe acute respiratory syndrome coronavirus | Q47733696 | ||
| SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus. | Q47770712 | ||
| New human coronavirus, HCoV-NL63, associated with severe lower respiratory tract disease in Australia | Q47866188 | ||
| Immune responses with DNA vaccines encoded different gene fragments of severe acute respiratory syndrome coronavirus in BALB/c mice | Q47871446 | ||
| Transmission dynamics of the etiological agent of SARS in Hong Kong: impact of public health interventions | Q47888803 | ||
| Severe acute respiratory syndrome coronavirus on hospital surfaces | Q47929806 | ||
| Frequent detection of human coronaviruses in clinical specimens from patients with respiratory tract infection by use of a novel real-time reverse-transcriptase polymerase chain reaction | Q48021682 | ||
| DNA vaccine of SARS-Cov S gene induces antibody response in mice | Q48029320 | ||
| Biological and genetic characterization of a hemagglutinating coronavirus isolated from a diarrhoeic child | Q48078807 | ||
| A new virus isolated from the human respiratory tract | Q45825116 | ||
| Inactivation of surrogate coronaviruses on hard surfaces by health care germicides. | Q45904883 | ||
| A new Sephadex-based method for removing microbicidal and cytotoxic residues when testing antiseptics against viruses: Experiments with a human coronavirus as a model. | Q45985533 | ||
| Efficacy of various disinfectants against SARS coronavirus | Q46516230 | ||
| Inactivation of SARS coronavirus by means of povidone-iodine, physical conditions and chemical reagents | Q46954531 | ||
| Coronavirus 229E-related pneumonia in immunocompromised patients | Q47623019 | ||
| Clinical and molecular epidemiological features of coronavirus HKU1-associated community-acquired pneumonia | Q47697594 | ||
| A multicentre collaboration to investigate the cause of severe acute respiratory syndrome. | Q51671710 | ||
| Effectiveness of precautions against droplets and contact in prevention of nosocomial transmission of severe acute respiratory syndrome (SARS). | Q51674509 | ||
| Rhinovirus and coronavirus infection-associated hospitalizations among older adults. | Q51717782 | ||
| Human respiratory coronavirus HKU1 versus other coronavirus infections in Italian hospitalised patients. | Q54562369 | ||
| Impact of human coronavirus infections in otherwise healthy children who attended an emergency department. | Q54574647 | ||
| Survival of surrogate coronaviruses in water. | Q54690124 | ||
| The morphology of three previously uncharacterized human respiratory viruses that grow in organ culture. | Q54690171 | ||
| Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus | Q57769050 | ||
| Human coronavirus gene expression in the brains of multiple sclerosis patients | Q67565726 | ||
| Effect of pH and temperature on the infectivity of human coronavirus 229E | Q69805494 | ||
| Survival characteristics of airborne human coronavirus 229E | Q70110374 | ||
| Effects of a "new" human respiratory virus in volunteers | Q72267375 | ||
| Carditis associated with coronavirus infection | Q72428284 | ||
| Isolation of rhinoviruses and coronaviruses from 38 colds in adults | Q72891515 | ||
| Association of coronavirus infection with neonatal necrotizing enterocolitis | Q72921456 | ||
| Survival of human coronaviruses 229E and OC43 in suspension and after drying on surfaces: a possible source of hospital-acquired infections | Q73053612 | ||
| Global surveillance for severe acute respiratory syndrome (SARS) | Q73335803 | ||
| Coronavirus pneumonia following autologous bone marrow transplantation for breast cancer | Q74619199 | ||
| Human (non-severe acute respiratory syndrome) coronavirus infections in hospitalised children in France | Q81592818 | ||
| Detection of human coronavirus NL63 and OC43 in children with acute respiratory infections in Niigata, Japan, between 2010 and 2011 | Q84212016 | ||
| Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia | Q24558699 | ||
| Transmission dynamics and control of severe acute respiratory syndrome | Q24654906 | ||
| Identification and containment of an outbreak of SARS in a community hospital | Q24678453 | ||
| Croup is associated with the novel coronavirus NL63 | Q24814848 | ||
| Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus | Q28188496 | ||
| Coronavirus as a possible cause of severe acute respiratory syndrome | Q28200848 | ||
| Bats are natural reservoirs of SARS-like coronaviruses | Q28274751 | ||
| Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants | Q28764574 | ||
| Identification of a new human coronavirus | Q29615906 | ||
| Identification of a novel coronavirus in patients with severe acute respiratory syndrome | Q29615907 | ||
| A novel coronavirus associated with severe acute respiratory syndrome | Q29617553 | ||
| A major outbreak of severe acute respiratory syndrome in Hong Kong | Q33347382 | ||
| Neuroinvasion by human respiratory coronaviruses | Q33604167 | ||
| Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice | Q33696283 | ||
| Complete genomic sequence of human coronavirus OC43: molecular clock analysis suggests a relatively recent zoonotic coronavirus transmission event | Q33717322 | ||
| Identification of a novel coronavirus in bats | Q33782401 | ||
| Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region. | Q33834543 | ||
| Molecular evolution analysis and geographic investigation of severe acute respiratory syndrome coronavirus-like virus in palm civets at an animal market and on farms | Q33987404 | ||
| Epidemiological determinants of spread of causal agent of severe acute respiratory syndrome in Hong Kong | Q34202150 | ||
| Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus | Q34247261 | ||
| Transmission of the severe acute respiratory syndrome on aircraft | Q34284622 | ||
| Severe acute respiratory syndrome (SARS) in Singapore: clinical features of index patient and initial contacts | Q34396455 | ||
| Evidence of human coronavirus HKU1 and human bocavirus in Australian children | Q34463761 | ||
| Immunopathogenesis of coronavirus infections: implications for SARS. | Q34472168 | ||
| Detection of the new human coronavirus HKU1: a report of 6 cases | Q34489739 | ||
| Molecular diversity of coronaviruses in bats. | Q34519162 | ||
| The SARS epidemic in Hong Kong | Q35204767 | ||
| A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge | Q35531454 | ||
| The severe acute respiratory syndrome | Q35610030 | ||
| Investigation of a nosocomial outbreak of severe acute respiratory syndrome (SARS) in Toronto, Canada. | Q35654437 | ||
| Severe acute respiratory syndrome-associated coronavirus in lung tissue | Q35879219 | ||
| SARS in hospital emergency room | Q35880638 | ||
| Development of antiviral therapy for severe acute respiratory syndrome. | Q36119173 | ||
| Acute viral infections of upper respiratory tract in elderly people living in the community: comparative, prospective, population based study of disease burden | Q36246809 | ||
| Physico-chemical properties of murine hepatitis virus, strain A 59. Brief report | Q36285763 | ||
| Recovery in tracheal organ cultures of novel viruses from patients with respiratory disease | Q36465731 | ||
| Chimeric coronavirus-like particles carrying severe acute respiratory syndrome coronavirus (SCoV) S protein protect mice against challenge with SCoV | Q36496355 | ||
| Coronaviruses and their therapy | Q36534375 | ||
| Human respiratory coronavirus OC43: genetic stability and neuroinvasion | Q36684214 | ||
| Conformational change of the coronavirus peplomer glycoprotein at pH 8.0 and 37 degrees C correlates with virus aggregation and virus-induced cell fusion | Q36808410 | ||
| The pediatric burden of human coronaviruses evaluated for twenty years | Q37396461 | ||
| Coronavirus infection and hospitalizations for acute respiratory illness in young children | Q37399614 | ||
| A previously undescribed coronavirus associated with respiratory disease in humans | Q37647570 | ||
| High-dose hydrocortisone reduces expression of the pro-inflammatory chemokines CXCL8 and CXCL10 in SARS coronavirus-infected intestinal cells | Q38332095 | ||
| The influence of pH on the growth and stability of transmissible gastroenteritis virusin vitro | Q39073877 | ||
| Persistent infection of human oligodendrocytic and neuroglial cell lines by human coronavirus 229E. | Q39550106 | ||
| Acute and persistent infection of human neural cell lines by human coronavirus OC43. | Q39550114 | ||
| Antiseptic properties of two calix[4]arenes derivatives on the human coronavirus 229E. | Q39653838 | ||
| Infection of primary cultures of human neural cells by human coronaviruses 229E and OC43. | Q39877907 | ||
| Prior immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV. | Q39926740 | ||
| Genetic variability of human coronavirus OC43-, 229E-, and NL63-like strains and their association with lower respiratory tract infections of hospitalized infants and immunocompromised patients | Q40276002 | ||
| Induction of protective immunity against severe acute respiratory syndrome coronavirus (SARS-CoV) infection using highly attenuated recombinant vaccinia virus DIs. | Q40282936 | ||
| A recombinant baculovirus-expressed S glycoprotein vaccine elicits high titers of SARS-associated coronavirus (SARS-CoV) neutralizing antibodies in mice | Q40312310 | ||
| Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine | Q40393493 | ||
| Ribavirin and interferon-beta synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines. | Q40479393 | ||
| Human coronavirus NL63, France | Q40501168 | ||
| Human coronavirus NL63 infection and other coronavirus infections in children hospitalized with acute respiratory disease in Hong Kong, China | Q40507931 | ||
| Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. | Q40510688 | ||
| Human coronavirus NL63 infection in Canada | Q40516855 | ||
| Evidence of a novel human coronavirus that is associated with respiratory tract disease in infants and young children | Q40516863 | ||
| A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice | Q40520942 | ||
| Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China | Q40554400 | ||
| Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study | Q40557821 | ||
| Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. | Q40559650 | ||
| An outbreak of coronavirus OC43 respiratory infection in Normandy, France | Q40561829 | ||
| Identification of severe acute respiratory syndrome in Canada | Q40562241 | ||
| Stability of SARS coronavirus in human specimens and environment and its sensitivity to heating and UV irradiation. | Q40614670 | ||
| Neonatal nosocomial respiratory infection with coronavirus: a prospective study in a neonatal intensive care unit | Q40684039 | ||
| Coronavirus infections of man associated with diseases other than the common cold | Q40864906 | ||
| Detection of coronavirus RNA and antigen in multiple sclerosis brain | Q41121992 | ||
| Antigenic and immunogenic characterization of recombinant baculovirus-expressed severe acute respiratory syndrome coronavirus spike protein: implication for vaccine design | Q42424192 | ||
| SARS vaccine protective in mice | Q42555546 | ||
| Chemical disinfection of non-porous inanimate surfaces experimentally contaminated with four human pathogenic viruses | Q43054231 | ||
| Possible role of an animal vector in the SARS outbreak at Amoy Gardens | Q43216944 | ||
| Canine coronavirus inactivation with physical and chemical agents | Q43222583 | ||
| The antiviral action of common household disinfectants and antiseptics against murine hepatitis virus, a potential surrogate for SARS coronavirus | Q43289583 | ||
| Coronavirus-related nosocomial viral respiratory infections in a neonatal and paediatric intensive care unit: a prospective study | Q43443600 | ||
| HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus | Q43541243 | ||
| A subcutaneously injected UV-inactivated SARS coronavirus vaccine elicits systemic humoral immunity in mice. | Q44110039 | ||
| Stability and inactivation of SARS coronavirus | Q44434982 | ||
| Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus | Q44483023 | ||
| Immunogenicity of SARS inactivated vaccine in BALB/c mice | Q44709506 | ||
| Inactivated SARS-CoV vaccine prepared from whole virus induces a high level of neutralizing antibodies in BALB/c mice | Q44961556 | ||
| Inactivated SARS-CoV vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entry | Q45141976 | ||
| A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses | Q45423400 | ||
| Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets | Q45501850 | ||
| Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. | Q45622393 | ||
| P275 | copyright license | Creative Commons Attribution 3.0 Unported | Q14947546 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | sepsis | Q183134 |
| virus | Q808 | ||
| P304 | page(s) | 3044-3068 | |
| P577 | publication date | 2012-11-12 | |
| P1433 | published in | Viruses | Q7935305 |
| P1476 | title | Human coronaviruses: insights into environmental resistance and its influence on the development of new antiseptic strategies | |
| P478 | volume | 4 |
| Q40436230 | A Melting Curve-Based Multiplex RT-qPCR Assay for Simultaneous Detection of Four Human Coronaviruses |
| Q89046119 | A new threat from an old enemy: Re‑emergence of coronavirus (Review) |
| Q96303899 | A quantitative and qualitative analysis of the COVID-19 pandemic model |
| Q33657624 | Antiviral natural products and herbal medicines |
| Q97521348 | Biocides and Novel Antimicrobial Agents for the Mitigation of Coronaviruses |
| Q98647338 | COVID-19 and saliva: A primer for dental health care professionals |
| Q101165767 | COVID-19-associated gastrointestinal and liver injury: clinical features and potential mechanisms |
| Q93189186 | COVID-19: A Recommendation to Examine the Effect of Mouthrinses with β-Cyclodextrin Combined with Citrox in Preventing Infection and Progression |
| Q90744942 | COVID-19: what has been learned and to be learned about the novel coronavirus disease |
| Q99582939 | Challenges and issues surrounding the use for translational research of human samples obtained during the COVID-19 pandemic from lung cancer patients |
| Q26746184 | Challenges presented by MERS corona virus, and SARS corona virus to global health |
| Q97520059 | Comparison of COVID-19 Pandemic Dynamics in Asian Countries with Statistical Modeling |
| Q99403247 | Concerns and strategies for wastewater treatment during COVID-19 pandemic to stop plausible transmission |
| Q50917182 | Coronavirus NL63-induced Adult Respiratory Distress Syndrome. |
| Q92055255 | Coronavirus-Days in Dermatology |
| Q40755043 | Detection of the Severe Acute Respiratory Syndrome-Related Coronavirus and Alphacoronavirus in the Bat Population of Taiwan |
| Q40336588 | Differential Expression of the Middle East Respiratory Syndrome Coronavirus Receptor in the Upper Respiratory Tracts of Humans and Dromedary Camels |
| Q99614581 | ERCP during the COVID-19 epidemic |
| Q40107887 | Emerging infectious diseases: Focus on infection control issues for novel coronaviruses (Severe Acute Respiratory Syndrome-CoV and Middle East Respiratory Syndrome-CoV), hemorrhagic fever viruses (Lassa and Ebola), and highly pathogenic avian influe |
| Q92035151 | Endoscopy in inflammatory bowel diseases during the COVID-19 pandemic and post-pandemic period |
| Q87945074 | Enteric involvement of coronaviruses: is faecal–oral transmission of SARS-CoV-2 possible? |
| Q96766850 | Environmental concern regarding the effect of humidity and temperature on 2019-nCoV survival: fact or fiction |
| Q104795285 | Evaluating splatter and settled aerosol during orthodontic debonding: implications for the COVID-19 pandemic |
| Q91912227 | Evolutionary perspectives on novel coronaviruses identified in pneumonia cases in China |
| Q64249495 | Global Epidemiology of Bat Coronaviruses |
| Q91516583 | Harmonizing the COVID-19 cacophony: People need guidance |
| Q91609670 | Hepatic and gastrointestinal involvement in coronavirus disease 2019 (COVID-19): What do we know till now? |
| Q99201268 | How can nanotechnology help to combat COVID-19? Opportunities and urgent need |
| Q99575594 | How to improve the chemical disinfection of contaminated surfaces by viruses, bacteria and fungus? |
| Q58702395 | Human Coronavirus Infections in Israel: Epidemiology, Clinical Symptoms and Summer Seasonality of HCoV-HKU1 |
| Q40932954 | Human coronaviruses in severe acute respiratory infection (SARI) cases in southwest India. |
| Q94603313 | Human coronaviruses with emphasis on the COVID-19 outbreak |
| Q38852292 | Monitoring Survivability and Infectivity of Porcine Epidemic Diarrhea Virus (PEDv) in the Infected On-Farm Earthen Manure Storages (EMS) |
| Q42243405 | Novel antiviral agents for respiratory viral infection in immunocompromised adults |
| Q59349689 | PCR array profiling of antiviral genes in human embryonic kidney cells expressing human coronavirus OC43 structural and accessory proteins |
| Q84579138 | Persistence of coronaviruses on inanimate surfaces and its inactivation with biocidal agents |
| Q104283628 | Physicochemical susceptibility of SARS-CoV-2 to disinfection and physical approach of prophylaxis |
| Q47142167 | Prevalence and genetic diversity analysis of human coronaviruses among cross-border children |
| Q38361184 | Protecting the frontline: designing an infection prevention platform for preventing emerging respiratory viral illnesses in healthcare personnel |
| Q102054053 | Quantitative analysis of particulate matter release during orthodontic procedures: a pilot study |
| Q89477874 | Recent discovery and development of inhibitors targeting coronaviruses |
| Q96129339 | Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19 |
| Q99565611 | Role of Environmental Temperature on the Attack rate and Case fatality rate of Coronavirus Disease 2019 (COVID-19) Pandemic |
| Q94672408 | SAFETY IN DIGESTIVE ENDOSCOPY PROCEDURES IN THE COVID ERA RECOMMENDATIONS IN PROGRES OF THE ITALIAN SOCIETY OF DIGESTIVE ENDOSCOPY |
| Q91598851 | Severe Acute Respiratory Syndrome (SARS) and Coronavirus disease-2019 (COVID-19): From Causes to Preventions in Hong Kong |
| Q93240889 | Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2): An Update |
| Q94569926 | Severe acute respiratory syndrome coronavirus 2 (the cause of COVID 19) in different types of clinical specimens and implications for cytopathology specimen: An editorial review with recommendations |
| Q94951743 | Spillover of SARS-CoV-2 into novel wild hosts in North America: A conceptual model for perpetuation of the pathogen |
| Q90648632 | Suggestions for infection prevention and control in digestive endoscopy during current 2019-nCoV pneumonia outbreak in Wuhan, Hubei province, China |
| Q41354809 | Survival of Enveloped and Non-Enveloped Viruses on Inanimate Surfaces |
| Q92104740 | Sustainable practice of ophthalmology during COVID-19: challenges and solutions |
| Q96647507 | Textile Masks and Surface Covers-A Spray Simulation Method and a "Universal Droplet Reduction Model" Against Respiratory Pandemics |
| Q95600578 | The flow physics of COVID-19 |
| Q93219808 | Topical preparations to reduce SARS-CoV-2 aerosolization in head and neck mucosal surgery |
| Q30381743 | Transmission of SARS and MERS coronaviruses and influenza virus in healthcare settings: the possible role of dry surface contamination. |
| Q98306954 | Volatile molecules for COVID-19: A possible pharmacological strategy? |
| Q90670164 | [New and rare pneumotropic viruses] |
Search more.